KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed/refractory (R/R) Mantle Cell Lymphoma (MCL): Results from Phase 2 of ZUMA-2 Wang, M., Munoz, J., Goy, A., Locke, F., Jacobson, C., Hill, B., Timmerman, J., Holmes, H., Jaglowski, S., Flinn, I., McSweeney, P., Miklos, D., Pagel, J., Kersten, M., Peng, W., Zheng, L., Rossi, J., Jain, R., Rao, A., Reagan, P. SPRINGERNATURE. 2020: 41–43

View details for Web of Science ID 000600556200033